THE EUROPE CELL AND GENE THERAPY MARKET SIZE TO CROSS USD 2.9 BILLION IN 2026, GROWING AT A CAGR OF 23% DURING THE PERIOD 2021–2026

Europe Cell and Gene Therapy Market Size, Share, Trends Analysis Report by Product (Cell Therapies and Gene Therapies); End-user (Hospitals, Cancer Care Centers, Wound Care Centers, and Others); Applications (Oncology, Dermatology, Musculoskeletal, and Others); and Geography (Europe); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

187 Pages

icon-table

47 Tables

icon-chart

84 Charts

icon-region

1 Regions

icon-country

7 Countries

icon-company

36 Companies

icon-market

4 Market Segment

EUROPE CELL AND GENE THERAPY MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) 2.9 BILLION (2026)
CAGR 23% (2021–2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Product (Cell Therapies and Gene Therapies); End-user (Hospitals, Cancer Care Centers, Wound Care Centers, and Others); Applications (Oncology, Dermatology, Musculoskeletal, and Others)
Geographic Analysis Europe
Countries Covered UK, Germany, France, Italy, Spain, Switzerland, and Netherlands

EUROPE CELL AND GENE THERAPY MARKET INSIGHTS

The Europe cell and gene therapy market size to cross USD 2.9 billion in 2026, growing at a CAGR of 23% during 2021-2026. The global cell and gene therapy market observes significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. Besides, the European market is witnessing steady growth due to increased funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products faster. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.

SNIPPETS

  • Gene therapies are likely to grow at the highest CAGR during the forecast period due to the high potential of these therapies to treat several diseases and ailments effectively.
  • The revenue share of oncology therapies is expected to touch approx. $13 billion by 2026 on account of rapid development in CAR-T cell therapies has high commercial potential for treating cancer.
  • While hospitals are expected to dominate the Europe cell and gene therapy market during the forecast period, cancer care centers are projected to grow at the highest rate.
  • Western Europe is likely to account for revenue of over $2.7 billion by 2026 because of the crucial role played by Germany, France, the UK, Italy, and Spain in the development of cell and gene therapies.

EUROPE CELL AND GENE THERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Product
  • End-user
  • Application
  • Geography

INSIGHTS BY PRODUCTS

A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling gene therapies' growth.  Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.

A surge in cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell therapy products drive the European cell therapy market growth. However, a low success rate of cell therapies and the high cost of cell-based research are expected to restrain the market growth during the forecast period.

INSIGHTS BY END-USER

Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in treating several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.

Cancer care centers accounted for over 20% of the Europe cell and gene therapy market share in 2020. These centers provide life-extending immunotherapy treatments to patients, enabling them to access the latest therapies instantly. The healthcare expenditure for cancer treatments has increased in Europe. There has been a new trend in cancer treatment. The introduction of CAR-T cell therapies and the increased usage of combination treatments and multi-indication treatments are the two recent and major cancer oncology treatments in Europe.

INSIGHTS BY APPLICATION

Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing patients' quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.

Wound care management constitutes a growing burden on public health expenditure and is incurring a high cost to the health care system. Acute wounds can be traumatic such as abrasions, lacerations, penetrating injuries and burns, or surgical wounds from surgical incisions. Burns remains one of the common injuries in Europe. Gene therapies are in the early stages; however, they display promising results for some rare genetic dermatology diseases and common skin conditions. Hence, positive clinical dividends and high potential to treat some acute wounds are expected to influence the cell and gene therapy market growth during the forecast period.

INSIGHTS BY GEOGRAPHY

Germany, France, the UK, Italy, and Spain play a significant role in the European cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. Besides, the target patient population is increasing across Europe; there were an estimated 3.9 million new cancer cases and 1.9 million cancer deaths in Europe in 2018. Besides, the prevalence surveys in the UK and Denmark indicate that there are 3–4 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes involved in the development of cell and gene therapies are expected to boost the market in Europe.

INSIGHTS BY VENDORS

Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of the presence of a large pool of target patient populations with chronic diseases such as cancer, wound disorders, diabetic foot ulcers, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors.  While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors prefer third-party service providers, including CMOs.

The Europe cell and gene therapy market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Product

  • Cell Therapies
  • Gene Therapies

End-user

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

Application

  • Oncology
  • Dermatology
  • Musculoskeletal
  • Others

Geography

  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Switzerland
    • Netherlands

Frequently Asked Questions

What is the Europe cell and gene therapy market size and growth rate during the forecast period?

The Europe cell and gene therapy market is growing at a CAGR of over 23%, reaching to market revenue of USD 2.9 billion by 2026.

What are the factors driving the demand for CAR-T therapy in the European region?

Increase in demand for CAR-T Therapies in Europe and rise in new product launches and approvals are the major factors driving the market growth.

How are strategic acquisitions aiding in market growth of cell and gene therapy products?

Vendors are strategically focusing on the launch of single-use bioprocessing products to remain competitive and gain traction in the market.

Which segments are expected to generate the highest revenues during the forecast period?

In terms of application, oncology is likely to account for the highest revenue contribution to the market.

Who are the leading vendors in the European cell and gene therapy market?

Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading vendors in the market.

Download Free Sample

The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021–2026.

The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period:

  • CMOs Offering Vector Manufacturing Services for Cell and Gene Therapy Companies
  • Robust Cell & Gene Therapies in the Pipeline
  • Increase in Strategic Acquisitions
  • Regulatory Support for Cell and Gene Therapy Products

Base Year:                  2020

Forecast Year:           2021–2026

The study considers the present scenario of the Europe cell and gene therapy market and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Prominent Vendors

  • Novartis
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Spark Therapeutics
  • Amgen
  • Gilead Sciences
  • Organogenesis

Other Prominent Vendors

  • APAC Biotech
    • Business Overview
    • Product Offerings
  • AVITA Medical
  • bluebird bio
  • CHIESI Farmaceutici
  • CollPlant
  • CO.DON
  • Human Stem Cells Institute PJSC (HSCI)
  • Medipost
  • NuVasive
  • Nipro
  • Orchard Therapeutics
  • RMS Regenerative Medical System
  • Orthocell
  • Osiris Therapeutics
  • Sibino GeneTech
  • Shanghai Sunway Biotech
  • Takeda Pharmaceutical Company
  • Terumo
  • Vericel

Emerging Investigational Vendors In Europe

  • Adaptimmune Therapeutics
    • Business Overview
  • AgenTus Therapeutics
  • Autolus
  • Cellecits
  • Celyad
  • CombiGene
  • EUKARŸS
  • Freeline Therapeutics
  • Innoskel
  • PsiOxus Therapeutics Ltd
  • SparingVision
  • uniQure

Product

  • Cell Therapies
  • Gene Therapies

End-user

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

Application

  • Oncology
  • Dermatology
  • Musculoskeletal
  • Others

Geography

  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Switzerland
    • Netherlands

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of The Study

4.3.1 Market Segmentation by Product

4.3.2 Market Segmentation by Application

4.3.3 Market Segmentation by End-Users

4.3.4 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 Overview

8 Market Opportunities & Trends

8.1 CMO Offering Vector-Manufacturing Services

8.2 Robust Cell & Gene Therapy Pipeline

8.3 Increase In Strategic Acquisitions

9 Market Growth Enablers

9.1 Regulatory Support For Cell And Gene Therapy Market

9.2 Increasing Demand For CAR-T Therapy In Europe

9.3 Product Launches And Approvals

10 Market Restraints

10.1 COVID-19 Impact on Cell And Gene Therapy Products

10.2 Increasing Pricing Pressure for Cell & Gene Therapy Products

10.3 Limitations of Gene Therapy Products

11 Market Landscape

11.1 Market Overview

11.2 Market Size & Forecast

11.3 Five Forces Analysis

11.3.1 Threat of New Entrants

11.3.2 Bargaining Power of Suppliers

11.3.3 Bargaining Power of Buyers

11.3.4 Threat of Substitutes

11.3.5 Competitive Rivalry

12 Product

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

12.3 Cell Therapy

12.3.1 Market Overview

12.3.2 Market Size & Forecast

12.4 Gene Therapy

12.4.1 Market Overview

12.4.2 Market Size & Forecast

13 Application

13.1 Market Snapshot & Growth Engine

13.2 Market Overview

13.3 Oncology

13.3.1 Market Overview

13.3.2 Market Size & Forecast

13.4 Dermatology

13.4.1 Market Overview

13.4.2 Market Size & Forecast

13.5 Musculoskeletal

13.5.1 Market Overview

13.5.2 Market Size & Forecast

13.6 Others

13.6.1 Market Overview

13.6.2 Market Size & Forecast

14 End-Users

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 Hospitals

14.3.1 Market Overview

14.3.2 Market Size & Forecast

14.4 Cancer Care Centers

14.4.1 Market Overview

14.4.2 Market Size & Forecast

14.5 Wound Care Centers

14.5.1 Market Overview

14.5.2 Market Size & Forecast

14.6 Others

14.6.1 Market Overview

14.6.2 Market Size & Forecast

15 Geography

15.1 Market Snapshot & Growth Engine

15.2 Geographic Overview

16 Western Europe

16.1 Market Overview

16.2 Market Size & Forecast

17 Rest of Europe

17.1 Market Overview

17.2 Market Size & Forecast

18 Key Countries

18.1 Germany: Market Size & Forecast

18.2 France: Market Size & Forecast

18.3 UK: Market Size & Forecast

18.4 Italy: Market Size & Forecast

18.5 Spain: Market Size & Forecast

18.6 Switzerland: Market Size & Forecast

18.7 The Netherlands: Market Size & Forecast

19 Competitive Landscape

19.1 Competition Overview

19.2 Market Share Analysis

19.2.1 Novartis

19.2.2 Spark Therapeutics

19.2.3 Amgen

19.2.4 Gilead Sciences

19.2.5 Organogenesis

20 Key Company Profiles

20.1 Novartis

20.1.1 Business Overview

20.1.2 Product Offerings

20.1.3 Key Strategies

20.1.4 Key Strengths

20.1.5 Key Opportunities

20.2 Spark Therapeutics

20.2.1 Business Overview

20.2.2 Product Offerings

20.2.3 Key Strategies

20.2.4 Key Strengths

20.2.5 Key Opportunities

20.3 AMGEN

20.3.1 Business Overview

20.3.2 Product Offerings

20.3.3 Key Strategies

20.3.4 Key Strengths

20.3.5 Key Opportunities

20.4 Gilead Sciences

20.4.1 Business Overview

20.4.2 Product Offerings

20.4.3 Key Strategies

20.4.4 Key Strengths

20.4.5 Key Opportunities

20.5 Organogenesis

20.5.1 Business Overview

20.5.2 Product Offerings

20.5.3 Key Strategies

20.5.4 Key Strengths

20.5.5 Key Opportunities

21 Other Prominent Vendors

21.1 APAC Biotech

21.1.1 Business Overview

21.1.2 Product Offerings

21.2 Avita Medical

21.2.1 Business Overview

21.2.2 Product Offerings

21.3 bluebird bio

21.3.1 Business Overview

21.3.2 Product Offerings

21.4 Chiesi Farmaceutici

21.4.1 Business Overview

21.4.2 Product Offerings

21.5 Collplant

21.5.1 Business Overview

21.5.2 Product Offerings

21.6 CO.DON

21.6.1 Business Overview

21.6.2 Product Offerings

21.7 Human Stem Cell Institute

21.7.1 Business Overview

21.7.2 Product Offerings

21.8 Medipost

21.8.1 Business Overview

21.8.2 Product Offerings

21.9 Nuvasive

21.9.1 Business Overview

21.9.2 Product Offerings

21.10 Nipro

21.10.1 Business Overview

21.10.2 Product Offerings

21.11 Orchard Therapeutics

21.11.1 Business Overview

21.11.2 Product Offerings

21.12 RMS Regenerative Medical System

21.12.1 Business Overview

21.12.2 Product Offerings

21.13 Orthocell

21.13.1 Business Overview

21.13.2 Product Offerings

21.14 Osiris Therapeutics

21.14.1 Business Overview

21.14.2 Product Offerings

21.15 Sibiono Genetech

21.15.1 Business Overview

21.15.2 Product Offerings

21.16 Shanghai Sunway Biotech

21.16.1 Business Overview

21.16.2 Product Offerings

21.17 Takeda Pharmaceutical Company

21.17.1 Business Overview

21.17.2 Product Offerings

21.18 Terumo

21.18.1 Business Overview

21.18.2 Product Offerings

21.19 Vericel

21.19.1 Business Overview

21.19.2 Product Offerings

22 Emerging Investigational Vendors In Europe

22.1 Adaptimmune Therapeutics

22.1.1 Business Overview

22.2 AgenTus

22.2.1 Business Overview

22.3 Autolus

22.3.1 Business Overview

22.4 Cellecits

22.4.1 Business Overview

22.5 Celyad

22.5.1 Business Overview

22.6 CombiGene

22.6.1 Business Overview

22.7 EUKARŸS

22.7.1 Business Overview

22.8 Freeline Therapeutics

22.8.1 Business Overview

22.9 Innoskel

22.9.1 Business Overview

22.10 PSIOXUS Therapeutics

22.10.1 Business Overview

22.11 Sparing Vision

22.11.1 Business Overview

22.12 Uniqure

22.12.1 Business Overview

23 Report Summary

23.1 Key Takeaways

23.2 Strategic Recommendations

24 Quantitative Summary

24.1 Market by Geography

24.2 Market by Product

24.3 Market by End-User

24.4 Market by Application

25 Appendix

25.1 Abbreviations

List Of Exhibits 

Exhibit 1             Cell and Gene Therapy Market in Europe: Segmentation

Exhibit 2             Market Size Calculation Approach 2020

Exhibit 3             ATMPs in Development in Europe 2019

Exhibit 4             Impact of CMOs Offering Vector-Manufacturing Services

Exhibit 5             Cell & Gene Therapy Supply Chain

Exhibit 6             Impact of Robust Cell & Gene Therapy Pipeline

Exhibit 7             Impact of Increase in Strategic Acquisitions

Exhibit 8             Impact of Regulatory Support for Cell and Gene Therapy Market

Exhibit 9             Regulatory Pathway for Market Approval in Europe

Exhibit 10           Impact of Increasing Demand for CAR-T Therapy in Europe

Exhibit 11           Impact of Product Launches and Approvals

Exhibit 12           Impact of Covid-19 on Cell and Gene Therapy Products

Exhibit 13           Gene Therapy Trials Disrupted by Covid-19

Exhibit 14           Impact of Increasing Pricing Pressure for the Cell and Gene Therapy Products

Exhibit 15           Impact of Limitations of Gene Therapy Products

Exhibit 16           Cell & Gene Therapy Expenditure by European Companies 2019 ($ billion)

Exhibit 17           Recent Development & Commercialization of Cell &Gene Therapy Products in Europe

Exhibit 18           Cell & Gene Therapy Market in Europe by Product 2020 & 2026 (% share)

Exhibit 19           Cell & Gene Therapy Market in Europe by Application 2020 & 2026 (% share)

Exhibit 20           Cell & Gene Therapy Market in Europe by End-Users 2020 & 2026 Percentage Share Comparison

Exhibit 21           Cell & Gene Therapy Market in Europe by Geography: 2020 & 2026 (% share)

Exhibit 22           Cell & Gene Therapy Market in Europe 2020–2026 ($ million)

Exhibit 23           Five Forces Analysis 2020

Exhibit 24           Incremental Growth by Product 2020 & 2026

Exhibit 25           Europe Cell & Gene Therapy Market Segmentation by Product

Exhibit 26           Europe Cell & Gene Therapy Market by Product: Incremental Growth

Exhibit 27           Europe Cell & Gene Therapy Market by Product: Absolute Growth

Exhibit 28           CAR-T Cell Treated Patients Registered in EMBT Registry

Exhibit 29           Cell & Gene Therapy Market by Cell Therapy in Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 30           Cell & Gene Therapy Market in Europe by Cell Therapy Product 2020–2026 ($ million)

Exhibit 31           Cell & Gene Therapy Market in Europe by Gene Therapy: Incremental Growth & Absolute Growth Comparison

Exhibit 32           Cell & Gene Therapy Market in Europe by Gene Therapy Product 2020–2026 ($ million)

Exhibit 33           Incremental Growth by Application 2020 & 2026

Exhibit 34           Europe Cell & Gene Therapy Market Segmentation by Application

Exhibit 35           Cell & Gene Therapy Market in Europe by Application: Incremental Growth

Exhibit 36           Europe Cell & Gene Therapy Market by Application: Absolute Growth

Exhibit 37           Europe Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison

Exhibit 38           Europe Cell & Gene Therapy Market by Oncology 2020–2026 ($ million)

Exhibit 39           Europe Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison

Exhibit 40           Cell & Gene Therapy Market in Europe by Dermatology 2020–2026 ($ million)

Exhibit 41           Europe Cell & Gene Therapy Market by Musculoskeletal: Incremental Growth & Absolute Growth Comparison

Exhibit 42           Cell & Gene Therapy Market in Europe by Musculoskeletal 2020–2026 ($ million)

Exhibit 43           Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison

Exhibit 44           Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)

Exhibit 45           Incremental Growth by End-Users 2020 & 2026

Exhibit 46           Europe Cell & Gene Therapy Market Segmentation by End-user

Exhibit 47           Cell & Gene Therapy Market in Europe by End-User: Incremental Growth

Exhibit 48           Cell & Gene Therapy Market in Europe by End-User: Absolute Growth

Exhibit 49           Cell & Gene Therapy Market in Europe by Hospitals: Incremental Growth & Absolute Growth Comparison

Exhibit 50           Cell & Gene Therapy Market in Europe by Hospitals 2020–2026 ($ million)

Exhibit 51           Cell & Gene Therapy Market in Europe by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison

Exhibit 52           Cell & Gene Therapy Market by Cancer Care Centers in Europe 2020–2026 ($ million)

Exhibit 53           Cell & Gene Therapy Market in Europe by Wound Care Centers: Incremental Growth & Absolute Growth Comparison

Exhibit 54           Cell & Gene Therapy Market by Wound Care Clinics in Europe 2020–2026 ($ million)

Exhibit 55           Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison

Exhibit 56           Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)

Exhibit 57           Incremental Growth by Geography 2020 & 2026

Exhibit 58           Europe Cell & Gene Therapy Market Segmentation by Geography

Exhibit 59           Cell & Gene Therapy Market in Europe by Geography: Incremental Growth

Exhibit 60           Cell & Gene Therapy Market in Europe by Geography: Absolute Growth

Exhibit 61           Global Audience of European Society of Cell & Gene Therapy

Exhibit 62           Main Contribution for European Society of Cell and Gene Therapy

Exhibit 63           Healthcare Expenditure of Western European Countries Relative to their GDP

Exhibit 64           Cell & Gene Therapy Market in Western Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 65           Cell & Gene Therapy Market in Western Europe 2020–2026 ($ million)

Exhibit 66           Healthcare Expenditure of Eastern European Countries Relative to their GDP

Exhibit 67           Cell & Gene Therapy Market in Rest of Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 68           Cell & Gene Therapy Market in Rest of Europe 2020–2026 ($ million)

Exhibit 69           Incremental Growth in Key Countries 2020 & 2026

Exhibit 70           Cell and Gene Therapy Market in Germany 2020–2026 ($ million)

Exhibit 71           Cell and Gene Therapy Market in France 2020–2026 ($ million)

Exhibit 72           Cell and Gene Therapy Market in UK 2020–2026 ($ million)

Exhibit 73           Cell and Gene Therapy Market in Italy 2020–2026 ($ million)

Exhibit 74           Cell and Gene Therapy Market in Spain 2020–2026 ($ million)

Exhibit 75           Cell and Gene Therapy Market in Switzerland 2020–2026 ($ million)

Exhibit 76           Cell and Gene Therapy Market in Netherlands 2020–2026 ($ million)

Exhibit 77           Novartis Revenue 2017-2019 ($ billion)

Exhibit 78           Novartis Segment Revenue Share 2019

Exhibit 79           Novartis: Regional Revenue Breakup 2019 (%)

Exhibit 80           Amgen Revenue 2019 - 2017 ($ billion)

Exhibit 81           Amgen: R&D Expenditure 2019 - 2017 ($ billion)

Exhibit 82           Gilead Sciences Revenue 2017–2019 ($ billion)

Exhibit 83           Gilead Sciences Research &Development Expenses 2017–2019 ($ billion)

Exhibit 84           Organogenesis Revenue 2018–2019 ($ million)

             

List Of Tables   

Table 1               Key Caveats

Table 2               Currency Conversion 2013−2020

Table 3               Comparison of Conventional Therapy Versus ATMPs

Table 4               CMO Vector Manufacturers in Europe

Table 5               Gene Therapies in Significant Stages of Clinical Pipeline

Table 6               Recent Strategic Acquisitions in Europe Cell & Gene Therapy Market

Table 7               Product Approvals & Launches

Table 8               Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe

Table 9               Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe

Table 10             Major Cell & Gene Therapy Products Approved in Europe

Table 11             Gene Therapy Product Approved BY EMA

Table 12             Oncology Application Based Cell & Gene Therapy Products

Table 13             Oncology Application Based Cell & Gene Therapy Products

Table 14             Oncology Application Based Cell & Gene Therapy Products

Table 15             Other Application Based Cell & Gene Therapy Products

Table 16             Novartis: Major Product Offerings

Table 17             Spark Therapeutics: Major Product Offerings

Table 18             Amgen: Major Product Offerings

Table 19             Gilead Sciences: Major Product Offerings

Table 20             Organogenesis: Major Product Offerings

Table 21             APAC Biotech: Major Product Offerings

Table 22             AVITA MEDICAL: Major Product Offerings

Table 23             bluebird bio: Major Product Offerings

Table 24             CHIESI Farmaceutici: Major Product Offerings

Table 25             COLLPLANT: Major Product Offerings

Table 26             CO.DON: Major Product Offerings

Table 27             Human Stem Cell Institute: Major Product Offerings

Table 28             MEDIPOST: Major Product Offerings

Table 29             NUVASIVE: Major Product Offerings

Table 30             NIPRO: Major Product Offerings

Table 31             Orchard Therapeutics: Major Product Offerings

Table 32             RMS Regenerative Medical System: Major Product Offerings

Table 33             Orthocell: Major Product Offerings

Table 34             Osiris Therapeutics: Major Product Offerings

Table 35             Sibino GeneTech: Major Product Offerings

Table 36             Shanghai Sunway Biotech: Major Product Offerings

Table 37             Takeda Pharmaceutical Company: Major Product Offerings

Table 38             Terumo: Major Product Offerings

Table 39             Vericel: Major Product Offerings

Table 40             Cell & Gene Therapy Market by Geography 2020−2026 ($ million)

Table 41             Cell& Gene Therapy Market by Geography 2020−2026 (%)

Table 42             Cell & Gene Therapy Market by Product 2020−2026 ($ million)

Table 43             Cell& Gene Therapy Market by Product 2020−2026 (%)

Table 44             Cell & Gene Therapy Market by End-User 2020−2026 ($ million)

Table 45             Cell& Gene Therapy Market by End-User 2020−2026 (%)

Table 46             Cell & Gene Therapy Market by Application 2020−2026 ($ million)

Table 47             Cell& Gene Therapy Market by Application 2020−2026 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date